%0 Journal Article
%T Effect of the ethylmethylhydroxypyridine succinate on the oxidative modification of serum proteins in patients with ischemic stroke
%A T.N. Khaybullin
%A E.Yu. Kravtsova
%A G.A.Martynova
%J Rational Pharmacotherapy in Cardiology
%D 2012
%I Rational Pharmacotherapy in Cardiology
%X Aim. To study the effect of ethylmethylhydroxypyridine succinate (EMHPS) on the protein oxidative modification (POM) in patients with acute ischemic stroke. (IS)Material and methods. Patients with IS (n=80) and 20 healthy subjects matched for age and sex (control group) were included in the study. IS patients were split into 2 groups: group 1 (n=39) received EMHPS in addition to standard treatment, and group 2 (n=41) - the standard therapy only. POM was studied by optical density of dinitrophenylhydrazone in wave lengths of 356, 370, 430, 530 nm in 1, 3 and 15 days after IS in patients of the both groups and in control.Results. Significant disorders of the antioxidant system were determined in patients with IS in the range of aldehyde and ketone derivates of dinitrophenylhydrazone in comparison with patients of control group. The highest POM level was observed in patients with atherothrombotic IS: optical density indexes of neutral and alkaline aldehyde and ketone derivates in blood serum proteins were maximal in all wave lengths. Next in order of POM levels decreasing followed patients with cardioembolic and haemodynamic IS and lastly patients with lacunar IS. POM increasing tendency was observed after 3 days in all patients with IS, especially in patients with atherothrombotic IS. A positive POM trend was found in all patients of the group 1 (p<0.05) in 15 days after disease onset. Patients with lacunar IS demonstrated optical density indexes in 530 nm wave length even comparable to those in the control group (0.18¡À0.01 and 0.2¡À0.03, respectively; p>0.05).Conclusion. EMHPS inclusion in the treatment of IS patients has a positive effect on the POM changes.
%K stroke
%K protein oxidative modification
%K ethylmethylhydroxypyridine succinate.
%U http://www.rpcardio.com/archive/article.php?ID=3600